Related Experiment Video
Updated: Feb 20, 2026
07:17
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
1.9K
Transformed follicular lymphoma.
Thais Fischer1, Natalia Pin Chuen Zing1, Carlos Sergio Chiattone2
1Irmandade Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil.
Annals of Hematology
|October 19, 2017
Summary
Follicular lymphoma transformation to aggressive lymphoma (t-FL) has a better prognosis in the rituximab era. This review examines recent research on t-FL, focusing on clinical significance and treatment strategies for diffuse large B cell lymphoma.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Follicular lymphoma (FL) is a common indolent non-Hodgkin lymphoma.
- Transformation to aggressive lymphoma (t-FL) historically portends poor prognosis.
- Recent data suggest improved outcomes and lower transformation risk in the rituximab era.
Purpose of the Study:
- To review current research on transformed follicular lymphoma (t-FL).
- To understand the clinical implications of FL transforming into diffuse large B cell lymphoma (DLBCL).
- To assess the impact of modern treatments on t-FL curability.
Main Methods:
- Literature review of recent studies on t-FL.
- Analysis of physiopathologic mechanisms including genetic, epigenetic, and microenvironmental factors.
- Evaluation of clinical outcomes and treatment strategies in the rituximab era.
Main Results:
- t-FL prognosis may be less severe than previously reported.
- The risk of transformation from FL to DLBCL might be lower with current therapies.
- Understanding of t-FL pathogenesis is evolving.
Conclusions:
- Transformed follicular lymphoma (t-FL) requires careful consideration of evolving prognostic data.
- Current treatment strategies may offer improved curability for t-FL.
- Further research is needed to optimize management of this lymphoma subtype.
